For readers studying ALC-0315 and related non-viral mRNA delivery systems, the central question is not whether a nanoparticle contains an ionizable lipid, but whether changes in the surrounding formulation alter translated protein output, tissue selectivity and intracellular delivery. Wang and colleagues addressed that question by combining degradable, side-chain-functionalized polymers with lipid components in polymer–lipid hybrid nanoparticles, or PLHNPs. The study is directly relevant as a neighboring formulation analysis, not as experimental validation of ALC-0315: ALC-0315 was not tested.
The original research article compared polymer-containing hybrids with lipid-only and SORT lipid nanoparticle benchmarks in mice. Its strongest evidence concerns how polymer charge, hydrophobic content and polymer fraction change functional mRNA expression in the lungs, liver and spleen.
Research Question
Can a shared ionizable-lipid framework be redirected toward different organs by adding degradable polymers with tunable charge and hydrophobic side chains, while retaining efficient mRNA encapsulation, intracellular delivery and short-term tolerability?
This is an important comparison for mRNA formulation research because lipid-only SORT systems can achieve organ-selective delivery, but their performance may be sensitive to chemical changes. The authors therefore examined whether polymers could provide another level of control without treating each organ and RNA cargo as an entirely separate platform.
Study Design and Methods
The main experiments used C57BL/6 mice and intravenous administration of Luc mRNA packaged in PLHNPs. Luciferase bioluminescence measured translated Luc protein in major organs, so these data represent functional expression rather than particle presence or labeled-RNA uptake. The reported mRNAs were Cap1-capped and contained N1-methylpseudouridine, as specified in the paper.
For the core comparisons, the authors combined SORT polymers with lipid systems containing an ionizable lipid, helper lipid, cholesterol and a PEG lipid. The 4A3-SC8 lipid composition served as a principal background formulation. Separate polymer families were associated with lung, liver or spleen delivery: permanently cationic side chains for lung-directed systems, ionizable side chains for liver-directed systems and anionic side chains for spleen-directed systems. The PEG lipid was part of these formulations, but it was not independently varied in the central mRNA comparisons; therefore, the study does not isolate a PEG-lipid-specific effect.
The investigation varied polymer side-chain balance, polymer fraction, alkyl-chain length and polymer backbone length. It also tested compatibility with an MC3-containing lipid formulation. Supporting experiments used Cre mRNA in Ai14 reporter mice, flow cytometry and tissue imaging to identify transfected cell populations. In that model, tdTomato fluorescence resulted from Cre-mediated activation of a genomic reporter, not from fluorescently labeled RNA. Additional experiments examined Cas9 mRNA with sgRNA, OVA mRNA, siRNA and circular RNA; the circRNA results should not be treated as linear mRNA results.
Main Findings
Charge and hydrophobic balance determined lung expression
The lung series produced a clear negative comparison. Polymers with a higher proportion of permanently cationic functionality and less hydrophobic alkyl content showed weak Luc expression. The authors proposed that excessive positive charge could hinder endosomal escape or that insufficient hydrophobic interaction could reduce particle stability, but these explanations remain mechanistic interpretations rather than fully resolved causal findings.
By contrast, polymers with greater alkyl content and lower cationic content performed better in the tested lung series. The PE4K-0.67C8-P1 composition was the strongest of the tested variants at the higher polymer fractions. Increasing the polymer fraction progressively shifted Luc expression from the liver toward the lungs within the same 4A3-SC8 lipid background. At the reported optimized polymer fractions, lung-targeted PLHNPs produced 13- to 26-fold higher mRNA expression than the lipid-only Lung-SORT benchmark containing 50% DOTAP, at the same administered dose. More than 95% of the measured expression signal was assigned to the lungs in that comparison.
The implication is narrower than a general claim that polymers outperform LNPs. The advantage depended on the polymer identity, polymer fraction and comparator. It shows that organ tropism can be reprogrammed within a hybrid formulation, but it does not establish that the same relationship would apply to ALC-0315 or to other ionizable lipids.
Liver and spleen delivery followed different composition rules
The liver and spleen results demonstrate that organ targeting was not monotonic with polymer content. Incorporating an ionizable 4L polymer into the 4A3-SC8 system retained liver tropism and significantly increased liver Luc expression relative to lipid-only 4A3-SC8 LNPs at the tested polymer fractions. The best liver performance in that series was associated with a particular balance between ionizable functionality and C8 hydrophobic content.
Spleen targeting behaved differently. Adding an anionic N1 polymer redirected expression from the liver toward the spleen, with the strongest spleen performance at low polymer incorporation. Increasing the polymer fraction further reduced spleen expression; the authors attributed this result to excessive negative charge impairing mRNA binding. The optimized spleen hybrid produced signals comparable to or higher than those from a lipid-only Spleen-SORT LNP containing 10% 18PA. This negative comparison matters because it shows that more targeting-associated polymer does not necessarily mean more functional expression.
The same design logic extended, but did not simply duplicate, in the MC3 comparison. The ionizable 4L polymer improved liver delivery while retaining liver tropism relative to the MC3 lipid-only background. The permanently cationic P1 polymer redirected expression away from the liver and toward the spleen and lungs, whereas the anionic N1 polymer favored spleen delivery. These results support compatibility with more than one ionizable-lipid class, but they remain formulation- and model-specific.
Expression was supported by functional cell delivery
The paper went beyond whole-organ Luc imaging by testing Cre mRNA in reporter mice. Liver-targeted PLHNPs produced tdTomato expression in the liver, while lung-targeted PLHNPs produced expression in the lungs. Tissue histology and flow cytometry corroborated those findings. The liver formulation transfected approximately 77% of total liver cells, including major hepatocyte, endothelial and immune-cell populations in the reported analysis. The lung formulation transfected more than 27% of total lung cells, with especially notable transfection among endothelial cells.
These experiments strengthen the interpretation that the particles delivered mRNA for translation in target tissues. They do not, however, quantify the number of mRNA molecules entering each cell. That distinction is important when comparing labeled-RNA uptake, intracellular accumulation and functional protein output: uptake can increase without a proportional increase in translation.
Uptake and endosomal escape were correlated with performance
Compared with lipid-only SORT LNP counterparts, representative PLHNPs showed increased cellular uptake and intracellular accumulation, enhanced membrane fusion and more efficient endosomal escape in the reported supporting analyses. The authors also observed changes in zeta potential, apparent pKa and serum protein corona composition. Across 56 representative hybrids, liver-selective particles generally showed apparent pKa values between 6 and 7, lung-selective particles tended to fall between 7 and 8, and spleen-selective particles between 4 and 6.
These measurements support a model in which the polymer changes surface properties and serum interactions, while the ionizable lipid remains important for pH-dependent membrane interactions. The paper presents this as a proposed mechanism: the data establish associations among composition, physicochemical properties and delivery outcomes, but they do not fully identify which corona proteins or intracellular events cause each organ preference.
Stability and short-term tolerability were encouraging but incomplete
Representative hybrids maintained their delivery efficiency and tissue tropism after storage testing and showed high colloidal stability in serum-containing media. Intermediate and longer alkyl chains generally produced more stable size, polydispersity and encapsulation results than shorter chains. Across additional RNA cargoes, the authors reported no systematic destabilization, although some parameters varied by formulation and cargo.
In the short-term mouse assessments, the study reported no observed toxicity, pathological abnormalities or inflammatory responses for the representative lung-, liver- and spleen-targeted systems. A specific assessment of the lung formulation found no evidence of thrombosis or adverse pulmonary effects. These observations support short-term tolerability in the tested models; they are not evidence of clinical safety, repeated-dose compatibility or complete material clearance.
Limitations
The study is a substantial original-research comparison, but its evidence is primarily a mouse proof of concept. Many in vivo groups contained only three or four animals, and some early optimization screens used fewer. The analyses were not uniformly blinded, and the authors noted that data distributions were assumed to be normal without formal testing.
The causal mechanism of organ tropism remains unresolved. Apparent pKa, surface charge, protein corona composition, uptake and endosomal escape all changed with formulation, making it difficult to assign the observed expression advantage to one variable. The study also did not directly measure in vivo polymer degradation kinetics, long-term clearance or repeated-dose safety. Finally, the findings should not be transferred directly to ALC-0315: the paper used 4A3-SC8 and MC3-related lipid systems, not ALC-0315, and its formulation comparisons do not establish performance for a commercial reagent or any exact product composition.
Source
Wang X, Tian Z, Pacheco Benitez A, et al. Tunable polymers for polymer–lipid hybrid nanoparticles facilitate controlled organ-selective RNA delivery. Nature Chemical Engineering. 2026;3:443–459. https://doi.org/10.1038/s44286-026-00425-9.